NAPSR News: Celgene has successful third quarter, sales of multiple myeloma drugs soar

WASHINGTON - Oct. 24, 2014 - PRLog -- Celgene Corporation had a remarkable financial third quarter earning a net income of $508 million for 2014 compared to $372 million in 2013. "We delivered outstanding third quarter results setting up a strong finish to 2014," said Bob Hugin, Chairman and Chief Executive Officer of Celgene Corporation. "Upcoming U.S. and European clinical and regulatory milestones and the meaningful progress we are making with our pipeline strengthen our position for future growth and success."

·         REVLIMID® approved for multiple myema (MM) had sales of $1,300 million, a 19% increase in revenue.  The company reported U.S. sales of $760 million and International sales of $540 million, both markets up 20% and 18%, respectively.

·         ABRAXANE®, the breast cancer treatment, had a 25% increase in sales amounting to $212 million for the third quarter. U.S. sales totaled $151 million and International sales of $61 million increasing 15% and 62%, respectively.

·         POMALYST®/IMNOVID® brought in an impressive $181 million in sales, an astounding increase of 102%. U.S. sales were $118 million and International sales were $63 million. The therapy is intended for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy

·         OTEZLA, Celgene’s breakthrough psoriatic arthritis therapy brought in $18 million in sales, at the end of July, the company reported that the drug, “captured the highest share of new patients of any brand in the U.S. psoriatic arthritis category”

·         Other contributors to Celgene’s impressive quarter include: THALOMID®, ISTODAX® and an authorized generic of VIDAZA® with sales amounting to $88 million in the third quarter of 2014 compared to $75 million in 2013.

CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!

With such industry leaders posting gains in profitability, they will need both certified and qualified individuals to promote their diversified product portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to market their product both proficiently and efficiently.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/